Step 1 topics → Respiratory → Leukotriene Modifiers

Leukotriene Modifiers

USMLE Step 1 trap: Confuses the mechanism of receptor antagonists (montelukast, zafirlukast) with the enzyme inhibitor (zileuton) among leukotriene modifiers. Montelukast and zafirlukast are cysteinyl leukotriene receptor (CysLT1) antagonists, while zileuton inhibits 5-lipoxygenase, blocking leukotriene synthesis upstream.

Leukotriene modifiers are a class of drugs that block the leukotriene pathway — either by inhibiting the enzyme that makes leukotrienes (zileuton blocks 5-lipoxygenase) or by blocking the receptor leukotrienes act on (montelukast and zafirlukast block CysLT1). They're used in asthma and allergic rhinitis, and USMLE Step 1 loves them because the class looks deceptively uniform — three drugs, one pathway — but they actually have distinct mechanisms, indications, and toxicity profiles that the exam exploits.

The exam tests this from three angles: pure mechanism recall (which drug does what), clinical application (when to choose a leukotriene modifier over or alongside other agents), and toxicity matching. The aspirin-exacerbated respiratory disease (Samter's triad) angle is particularly high yield because it requires you to connect COX inhibition → arachidonic acid shunting → excess leukotrienes → why these drugs specifically help. Passage-based questions may describe a patient with asthma who worsens after taking NSAIDs and ask you to identify the best add-on therapy.

What trips students up most is treating all three drugs as interchangeable. They are not. Zileuton is an enzyme inhibitor; the other two are receptor antagonists. And each has a distinct side effect the exam likes to test: zileuton causes hepatotoxicity, zafirlukast inhibits CYP enzymes causing drug interactions, and montelukast carries an FDA black box warning for neuropsychiatric effects including suicidality. USMLE Step 1 will give you a vignette that implies one of these toxicities and ask you to name the drug or mechanism responsible — knowing the distinctions is the only way through.

From real student decks
65%have cards covering this topic
43%have mature cards

Common misconceptions

Common mistake
Wrong: Montelukast and zileuton have the same mechanism of action.
Right: Montelukast and zafirlukast are cysteinyl leukotriene receptor (CysLT1) antagonists, while zileuton inhibits 5-lipoxygenase, blocking leukotriene synthesis upstream.
Montelukast and zileuton are both leukotriene modifiers, but they act at completely different points in the pathway. Montelukast (and zafirlukast) sit at the receptor level — they block CysLT1, the receptor that leukotrienes bind to cause bronchoconstriction and inflammation. Zileuton acts upstream by inhibiting 5-lipoxygenase, the enzyme that converts arachidonic acid into leukotrienes in the first place. Think of it as blocking the message versus blocking the factory — same outcome, different leverage points, different clinical implications and side effects.
Common mistake
Wrong: Leukotriene modifiers are only useful for allergic asthma and have no role in aspirin-exacerbated respiratory disease.
Right: Leukotriene modifiers are particularly effective in aspirin-exacerbated respiratory disease (Samter's triad) because COX inhibition by aspirin shunts arachidonic acid toward the lipoxygenase pathway, increasing leukotriene production.
Aspirin-exacerbated respiratory disease (Samter's triad: asthma + nasal polyps + aspirin sensitivity) is actually a prime indication for leukotriene modifiers, not a contraindication or irrelevant scenario. When aspirin or NSAIDs block COX-1, arachidonic acid can't go down the prostaglandin pathway, so it gets shunted toward 5-lipoxygenase and excess leukotrienes are produced — this is exactly what triggers bronchoconstriction in these patients. Blocking either leukotriene synthesis (zileuton) or the receptor (montelukast) directly addresses the underlying mechanism, making this one of the strongest specific indications for this drug class.
Common mistake
Gap: Missing awareness of the distinct toxicity profiles of leukotriene modifiers: zileuton (hepatotoxicity), zafirlukast (CYP interactions), montelukast (neuropsychiatric effects)
Zileuton is associated with hepatotoxicity and requires liver function test monitoring, while zafirlukast can inhibit CYP enzymes and cause drug interactions; montelukast has been linked to neuropsychiatric side effects including suicidality.
Each leukotriene modifier has a distinct toxicity you need to match to the right drug. Zileuton is hepatotoxic — patients on it need regular liver function test monitoring, and a vignette describing elevated transaminases in an asthma patient should make you think zileuton first. Zafirlukast inhibits CYP2C9 and CYP3A4, which means it raises levels of warfarin and other CYP-metabolized drugs — if a question describes a patient whose INR unexpectedly climbs after a new asthma medication, zafirlukast is the culprit. Montelukast carries an FDA black box warning for neuropsychiatric effects including agitation, depression, and suicidality — a vignette with a child or adult on asthma medication developing mood changes should point you there.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the three leukotriene modifier drugs, which are CysLT1 receptor antagonists (montelukast, zafirlukast) versus which is a 5-lipoxygenase enzyme inhibitor (zileuton), and why that mechanistic difference matters.
  2. Recognize the clinical indications for leukotriene modifiers, including mild persistent asthma, exercise-induced bronchospasm, allergic rhinitis, and especially aspirin-exacerbated respiratory disease (Samter's triad).
  3. Identify the distinct toxicity profile for each drug: zileuton requires LFT monitoring for hepatotoxicity, zafirlukast inhibits CYP450 and causes drug interactions, and montelukast is associated with neuropsychiatric side effects including depression and suicidality.

Can you avoid these mistakes?

A patient with asthma and nasal polyps reports that ibuprofen consistently triggers severe wheezing. You add a leukotriene modifier to her regimen. What is the mechanism by which NSAIDs worsen this patient's asthma, and why do leukotriene modifiers specifically help?
Match each drug to its correct mechanism: montelukast, zafirlukast, zileuton. Which inhibits an enzyme, and which block a receptor? Name the enzyme and the receptor.
A 35-year-old man on zileuton for asthma comes in for a routine visit. His AST and ALT are three times the upper limit of normal. He denies alcohol use. What is the most likely explanation, and what monitoring should have been in place?
A patient taking warfarin for atrial fibrillation is started on a leukotriene modifier for allergic rhinitis. Two weeks later his INR is supratherapeutic. Which leukotriene modifier is most likely responsible, and what is the mechanism of the interaction?

Related topics

Lung Development Stages Surfactant Production and Neonatal RDS Bronchopulmonary Dysplasia Congenital Diaphragmatic Hernia

See how your Anki deck covers this topic.

Upload your deck for a free audit →